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ABSTRACT 
Background and aim: Myxoma is the most common type of primary cardiac neoplasm, but 
the clinical characteristics and long term outcome are less known in the elderly in China.  
Methods: We analyzed medical records of 112 consecutive patients who underwent operative 
resection of cardiac myxoma between December 1988 and December 2010 in our hospital. 
Their data were retrospectively analyzed and the difference between two age groups (< 60 
years, n = 87 and ≥ 60 years, n = 25) was compared. 
Results: The mean age of 112 patients was 48.8 ± 12.5 (range 13 ~ 75) years, and 66 patients 
(58.9 %) were female. The interval from onset of symptoms to diagnosis was 12 months and 
the most common presenting symptoms were chest distress (66 patients 58.9 %), followed by 
palpitations (55 patients, 49.1 %) and dyspnea (47 patients, 42.0 %). Mitral valve diastolic 
murmur was heard in 67 (59.1 %) patients. The tumor was located in the left atrium in 96 
(85.8 %) patients. There were no in-hospital death. During follow-up ranged between one and 
twenty-one (7.3 ± 5.3) years, there was no malignancy. Myxoma recurred in 3 (2.7 %) pa-
tients and deaths occurred in 5 (4.5 %) patients. The 5 and 15 years survival was 97.8 % and 
89.5 %, respectively. To compare with the younger patients, the elderly have higher ratios of 
concomitant hypertension, fewer complaints of dyspnea and chest distress (p < 0.05).  
Conclusion: The elderly have lower complaints of dyspnea and chest distress, surgical treat-
ment is associated with low long-term mortality and recurrence rate even in the elder patients. 
 
Keywords: Cardiac myxoma, clinical characteristics, outcome, the elderly 
 
 
 
INTRODUCTION 
Cardiac myxoma is not common, their 
prevalence ranges from 0.001 % to 0.3 % in 
various series (Reynen, 1995; Markel et al., 
1987). However, large clinical observation 
studies shown that the incidence of primary 
cardiac tumor was as high as 0.3 %-0.81 % 
of all heart operations, and primary myxo-
mas composed 40 %–96.7 % of all cardiac 
tumors (MacGowan et al., 1993; Sezai, 
1990; Yu et al., 2007). 
Although more patients present ob-
structtive, embolic and constitutional symp-
toms, the incidence of asymptomatic myx-
oma tended to increase and the accidental 
diagnosis is relatively frequent, as a result 
of the development of cardiac imaging, par-
ticularly echocardiography (Matebele et al., 
2010; Roberts, 1997; Holley et al., 1995). 
Surgical resection is the only recommenda-
tion of treatment, with perioperative mortal-
ity of 0 % to 5 %, recurrence of 3 % to 8 % 
in sporadic cases and 20 % in familial 
myxomas (Gaszewska-Żurek et al., 2011; 
Oliveira et al., 2010). 
There are few reports in China about the 
clinical presentation and outcome especial-
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ly in the elder patients. This retrospective 
study aims to describe presentations and 
surgical management, to assess the survival 
in hospital and during the long-term follow-
up, and to find the possible difference in 
two different age groups in patients under-
went cardiac myxoma resection in our hos-
pital.  
 
PATIENTS AND METHODS 
The medical records of 125 patients 
who were diagnosed as cardiac tumor in the 
department of cardiac surgery between De-
cember 1988 and December 2010 were ret-
rospectively analyzed. 112 patients of spo-
radic type were histologically diagnosed as 
myxoma and the difference between two 
age groups (< 60 years and ≥ 60 years) was 
compared. Patients were invited clinic visit, 
telephone interviews or otherwise to their 
door. The following information was col-
lected: presenting symptoms, location of 
tumor, approach to surgical management, 
in-hospital mortality and long-term out-
come.  
The tumors were resected by median 
sternotomy with cardioplegia and cardio-
pulmonary bypass. The right atrial tumor 
was resected via a right atriotomy, the left 
atrial and left ventricle tumors were resect-
ed transeptally, the right ventricular myxo-
ma was resected through tricuspid valve 
oral. In all cases, the myxoma was removed 
with adequate tissue margin (0.5–1 cm 
margin around the stalk) and full thickness 
excision of the base tissue, followed by clo-
sure of the remaining interatrial communi-
cation, and surgical completeness was con-
firmed by histopathology. During follow-
up, patient survival and complication rates 
were analyzed and transthoracic echocardi-
ography (TTE) was performed. Angio-
graphy was performed in 45 patients to rule 
out concomitant pathology such as valvular 
and coronary disease. The study was ap-
proved by the hospital ethics committee and 
all patients gave informed consent for par-
ticipation in the study. 
Statistical analysis 
The continuous numerical values were 
expressed by means ± SD. The category 
‘variables’ was expressed in percentages. 
The chi-square test was used for categorical 
variables, and the Student’s t test was used 
for continuous variables. Long-term surviv-
al was analyzed by Cox regression and Lo-
gistical regression analysis was used for the 
multivariate analysis. A value of p<0.05 
was considered significant. The analysis 
was performed using SPSS version 19.0 
(SPSS Inc., Chicago, USA).  
 
RESULTS 
Patients mean age was 48.8 ± 12.5 years 
(range, 13 to 75 years) and 66 patients 
(58.9 %) were female. Presenting symp-
toms include chest distress which occurred 
in 66 patients (58.9 %), palpitations in 55 
(49.1 %), dyspnea in 47 patients (42.0 %), 
cerebral embolism in 9(8.0 %), lower ex-
tremity embolism in 6 (5.4 %) including 2 
coexist with cerebral embolism, syncope in 
10 (8.9 %), constitutional (weakness, fever, 
arthralgia) in 31 (27.7 %) patients, and 7 
(6.3 %) patients had no symptoms (Table 
1). 
The mean duration from onset of symp-
toms to diagnosis was about twelve months 
(range, 3 days to 132 months). Mitral valve 
diastolic murmur was heard in 67 (59.1 %) 
patients, atrial fibrillation was recorded in 8 
(7.1 %) by electrocardiography, cardiomeg-
aly was detected in 28 (25.0 %) patients by 
chest X-ray, PAH was reported in 6 (5.4 %) 
patients by echocardiography. 
Comorbidities include CAD in 9 
(8.0 %) patients, hypertension in 11 
(9.8 %), diabetes in 5 (4.5 %), moderate to 
significant mitral insufficiency in 5 (4.5 %), 
moderate to significant tricuspid insuffi-
ciency in 15 (13.4 %), patent ductus arterio-
sus（PDA）in 1, patent foramen ovale in 5 
(4.5 %) (Table 1). 
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Table 1: Clinical characteristics of myxomas 
 < 60 years 
No. (%) 
> 60 age 
No. (%) 
P value Total (112 cases) 
No. (%) 
Age (years)* 44.09 + 9.82 65.08 + 4.29 0.000 48.78 + 12.48 
Female 50 (57.5 %) 16 (64.0 %) 0.648 66 (58.9 %) 
Symptoms:     
Symptom duration 
(month)* 
11.01 + 20.33 15.65 + 31.68 0.381 12.04 + 23.26 
Dyspnea 43 (49.4 %) 4 (16.0 %) 0.003 47 (42.0 %) 
Palpitation 45 (51.7 %) 10 (40.0 %) 0.367 55. (49.1 %) 
Chest distress 56 (64.4 %) 10 (40.0 %) 0.038 66 (58.9 %) 
Syncope 6 (6.9 %) 4 (16.0 %) 0.226 10 (8.9 %) 
Embolic event 7 (8.0 %) 6 (24.0 %) 0.069 13 (11.6 %) 
Cerebral embolism 4 (4.6 %) 5 (20.0 %) 0.025 9 (8.0 %) 
Limb embolism 4 (4.6 %) 2 (8.0 %) 0.614 6 (5.4 %) 
Weakness 12 (13.8 %) 7 (28.0 %) 0.129 19 (17.0 %) 
Fever 5 (5.7 %) 3 (12.0 %) 0.374 8 (7.1 %) 
Arthralgia 2 (2.3 %) 2 (8.0 %) 0.215 4 (3.6 %) 
Asymptomatic 4 (4.6 %) 3 (12.0 %) 0.184 7 (6.3 %) 
Mitral valve murmur 4 (4.7 %) 1 (4.0 %) 1.000 5 (4.5 %) 
Atrial fibrillation 6 (6.9 %) 2 (8.0 %) 1.000 8 (7.1 %) 
Cardiomegaly 19 (21.8 %) 9 (36.0 %) 0.019 28 (25.0 %) 
PAH 5 (5.8 %) 1 (4.0 %) 1.000 6 (5.4 %) 
Comorbidities:     
CAD 6 (6.9 %) 3 (12.0 %) 0.415 9 (8.0 %) 
Hypertension 5 (5.7 %) 6 (24.0 %) 0.015 11 (9.8 %) 
Diabetes 3 (3.4 %) 2 (8.0 %) 0.310 5 (4.5 %) 
Patent foramen ovale 3 (3.4 %) 2 (8.0 %) 0.310 5 (4.5 %) 
MVD 4 (4.7 %) 1 (4.0 %) 0.183 5 (4.5 %) 
TVD 14 (16.1 %) 1 (4.0 %) 0.183 15 (13.4 %) 
* continuous numerical values were expressed by means ± SD 
CAD, coronary artery disease; PAH, pulmonary artery hypertension; MVD, Mitral valve deficiency; 
TVD,Tricuspid valve deficiency 
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Tumor location was as follows: left 
atrium in 96 (85.8 %), right atrium in 8 
(7.2 %), bi-atrium in 1(0.9 %), mitral valve 
anterior leaflet in 1 (0.9 %), left ventricle in 
4(3.6 %) and right ventricle in 1 (0.9 %) 
patient. Tumor volumes were 60.05 ± 
68.97 cm3 (Table 2). 
The following associated procedures 
were performed: mitral replacement in 1 
(0.9 %) case, tricuspid replacement in 8 
(7.1 %), coronary artery bypass graft in 3 
(2.7 %), ligation of patent ductus arteriosis 
in 1 and atrial septal defect suture in 1 (Ta-
ble 3). 
 
In-hospital deaths and complications  
There were no in-hospital deaths. Cere-
bral embolism was noted in 1 (0.9 %) pa-
tient, new atrial fibrillation was noted in 3 
(3.4 %) patients and all were successfully 
treated pharmacologically (Table 4). 
 
 
Table 2: Location and volume of tumor 
 < 60 years 
No. (%) 
> 60 age 
No. (%) 
P value Total (112 cases) 
No. (%) 
LA septum 57 (65.5 %) 17 (68.0 %) 1.000 74 (66.1 %) 
LA wall 15 (17.5 %9 5 (20.0 %) 0.763 20 (17.0 %) 
LA wall & septum 2 (2.3 %) 0 (0.0 %) 0.398 2 (1.8 %) 
RA septum 1 (1.1 %) 0 (0.0 %) 1.000 1 (0.9 %) 
RA wall 6 (6.9 %) 1 (4.0 %) 1.000 7 (6.3 %) 
RV 1 (1.1 %) 0 (0.0 %) 1.000 1 (0.9 %) 
LV 3 (3.4 %) 1 (4.0 %) 1.000 4 (3.6 %) 
LA & RV 1 (1.1 %) 0 (0.0 %) 1.000 1 (0.9 %) 
MV anterior leaf 1 (1.1 %) 1 (4.0 %) 0.398 2 (1.8 %) 
Tumor volume (cm3) 70.05 + 73.61 25.26 + 30.93 0.004 60.05 + 68.97 
* continuous numerical values were expressed by means ± SD 
LA, left atrial; RA, right atrial; LV, left ventricular; RV, right ventricular; MV, mitral valve  
 
Table 3: Concominant surgical procedures 
 < 60 years 
No. (%) 
> 60 age 
No. (%) 
P value Total (119 cases) 
No. (%) 
CABG 1 (2.3 %) 1 (4.0 %) 0.535 3 (2.7 %) 
TVR 7 (8.0 %) 1 (4.0 %) 0.681 8 (7.1 %) 
MVR 1 (4.0 %) 0 (0.0 %) 1.000 1 (0.9 %) 
Ligation of PDA 1 (4.0 %) 0 (0.0 %) 1.000 1 (0.9 %) 
Repair of ASD 1 (4.0 %) 0 (0.0 %) 1.000 1 (0.9 %) 
CABG, coronary artery bypass graft; TVR，tricuspid valve replacement; ASD,atrial septal defect; 
PDA, patent ductus arteriosis 
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Long-term follow-up 
All patients received follow-up for a 
mean duration of 7.26 ± 5.56 (1-21) years. 
There were no malignancies. Myxoma re-
curred in 3 (2.7 %) patients whose age was 
< 60 years, and no variable was correlated 
with recurrence by logistic analysis, even 
though syncope was correlated positively 
with it on univariate analysis. In our series, 
1 recurrence for four times (1 %) was de-
tected in a 24 year old male patient after 
initial operation (3 year in left atrium, 8 
year in right atrium, 14 and 19 years in left 
atrium). The original tumors located in bi-
atria, the location of recurrence was in the 
original place. Another case of a 53 year 
old man was diagnosed as left ventricle 
myxoma and resection followed without 
delay. During a follow-up, a myxoma was 
found in the left atrium 4 years later and in 
the same atrium 18 months later. The third 
patient was a 53 year old man by whom 
originally a myxoma in the left atrium was 
found, but 15 years later multiple myxoma 
were found in bi-atria and right ventricle 
and resections of the three chamber myxo-
ma were done simultaneously.  
Death occurred in 5 (4.5 %) patients in-
cluding 1 case whose age was > 60 years 
and 4 cases in the other age group (p > 
0.05). Table 5 lists the positively correlated 
variables on logistic analysis by mortality, 
which includes asymptomatic, arthralgia 
and larger tumor volume. The death causes 
were cerebral hemorrhage in 1 patient, renal 
failure in 1 patient and progressive HF in 3 
patients.  
Based on the Cox regression, the pro-
portion of patients surviving 5 and 15 years 
was 97.8 % and 89.5 %, respectively (Fig-
ure 1).  
Table 6 shows that the complaint of 
weakness and syncope were positively cor-
related with clinical embolic events. 
To compare with the younger patients, 
the elderly have higher ratios of hyperten-
tion, cerebral embolism and cardiomegaly, 
fewer complaints of dyspnea and chest di-
stress (all p < 0.05). But there was no sig-
nificant difference in other clinical charac-
teristics, tumor locations, recurrence and 
mortality between the two age groups. 
 
Table 4: Surgical results  
Results < 60 years 
No. (%) 
> 60 age 
No. (%) 
P value Total (112 cases) 
No. (%) 
In-hospital mortality 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 
In-hospital AF 3 (3.4 %) 1 (4.0 %) 1.000 4 (3.6 %) 
In-hospital embolism 1 (1.1 %) 0 (0.0 %) 1.000 1 (0.9 %) 
Late mortality 4 (4.7 %) 1 (4.0 %) 1.000 5 (4.5 %) 
Recurrence 3 (2.7 %) 0 (0.0 %) 0.000 3 (2.7 %) 
 
Table 5: Logistic analysis of variable by mortality 
Variable Death  
(n = 5) 
Survival  
(n = 107) 
B P 
Recurrence 2 (40.0 %) 1 (0.9 %) 5.308 0.001 
Arthralgia  1 (20.0 %9 3 (2.8 %) 3.517 0.022 
MW anterior leaf 1 (20.0 %) 1 (0.9 %) 4.615 0.008 
All variables in Table 1 and 2 were used in the logistic analysis. 
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Table 6: Logistic analysis of variable by clinical embolism 
Variable Embolism  
(n = 13) 
No embolism 
(n = 99) 
B P 
Dyspnea 2 (15.4 %) 45 (45.5 %) -1.617 0.058 
Weakness 5 (38.5 %) 14 (14.1 %) 2.021 0.018 
Syncope 4 (30.8 %) 6 (6.1 %) 2.081 0.011 
LV wall 4 (30.8 %) 16 (16.2 %) 1.355 0.087 
All variables in Table 1 and 2 were used in the logistic analysis. 
 
 
Figure 1: Based on the Cox regression, the 
proportion of patients surviving 5 and 15 years 
were 97.8 % and 89.5 %, respectively. All 112 
patients completed the follow-up without cen-
sored cases. 
 
DISCUSSION 
Various studies on autopsy and surgical 
practice have shown different incidence of 
primary heart tumors including myxoma 
(Reynen, 1995; Holley et al., 1995). In our 
series, the incidence of myxoma was 
0.81 % of all patients who underwent vari-
ous types of cardiac surgery (data not 
shown), which is relatively high than re-
ported by others.  
Although myxoma occur more frequent-
ly between the age of 30 and 40 years, it’s 
not rare in the elderly (Pinede et al., 2001). 
The average age ranged from 13 to 75 years 
old in our series, the elderly comprise 
22.5 % of all the patients, while the oldest 
person is 95 years of age as referred by 
Hudson (1965).  
The dominant symptom in this series is 
congestive heart failure due to obstruction 
of the mitral valve which was similar to 
those previously reported (Piazza et al., 
2004; Attum et al., 1987; Loire, 1996). The 
higher incidence of cardiomegaly in the el-
derly may be due to more comorbidities 
with advanced age such as hypertension. 
The low complaint of dyspnea and chest 
distress may be due to their reluctance to 
complain in the elderly.  
Embolic episodes are reported from 
28 % to 45 % of cases and may involve the 
brain, kidneys or limbs (Bhan et al., 1998; 
Ha et al., 1999; Gabe et al., 2002). In our 
series, 8.0 % of the patients in < 60 year 
group and 24.0 % in the other group suf-
fered from embolization, nine of them in 
the central nervous system, two combined 
with an embolus in the leg and four in the 
legs only. It was previously reported that 
smaller tumors with irregular surface more 
commonly result in embolic events (Oli-
veira et al., 2010). Furthermore, IL-6 and 
MMPs were considered to play a possible 
role in embolism formation, but the real 
causes are still uncertain (Orlandi et al., 
2005). 
Multivariate regression analysis of this 
sample shows that weakness and syncope 
were positively related with embolic events. 
This suggested that we should pay more 
attention to the patients who present the two 
symptoms to find the possible embolism. 
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What are considered constitutional 
symptoms (fever, weakness, arthralgia) oc-
curred in 27.7 % of the patients, which cor-
responded to that in previous reports (from 
5 % to 74 %) (Gabe et al., 2002; Meyns et 
al., 1993).  
As in previous studies (Yu et al., 2006; 
Perek et al., 2011), the majority of myxo-
mas located in the left atrium, followed by 
the right atrium and then the ventricles. 
It is reported that cardiac myxoma ex-
hibits rapid growth, and most patients show 
advanced symptoms at the time of surgery 
(Bhan et al., 1998). But possibly due to the 
decreasing trends in the size and weight of 
myxoma, the incidence of asymptomatic 
myxoma has increased, which was 6.3 % in 
our present result, and 0 % to 26 % in other 
reports (Yuda et al., 2002; Grande et al., 
1993). 
Some authors pointed out that the clini-
cal examination does not provide many 
clues to the diagnosis (Meyns et al., 1993). 
On auscultation, the well-described ‘tumor 
plop’ was only recorded in six patients in 
our series, but diastolic mitral murmur was 
heard in 59.1 % of the patients. So a careful 
listening of the heart is still a useful way 
leading to diagnosis. 
It has been reported that TEE has led to 
the increase in the incidence of myxoma 
diagnosed preoperatively by 2 to 7 times, 
and the proportion of patients who under-
went surgery before symptom has also in-
creased (Yuda et al., 2002; Fyke et al., 
1985). All patients in our group were diag-
nosed by TEE before surgery, which is con-
sistent with that reported by others (Yuda et 
al., 2002). All this supports the extensive 
use of echocardiography for medical check-
up and as preoperative screening for non-
cardiovascular disease in all patients, be-
cause echocardiography is a non-invasive 
investigation at a minimal cost with an ac-
curacy approaching 100 % (Perek et al., 
2011; Becker et al., 2008). 
It is well established that surgical re-
moval of myxoma is related with peri-
operative mortality from 0 % to 7.5 % 
(D'Alfonso et al., 2008; Selkane et al., 
2003). The zero in-hospital mortality was 
confirmed in our series. 
The most common in-hospital compli-
cation was AF which was diagnosed in 3 
patients. All of them received routine anti-
coagulation treatment, and no late thrombo-
embolic complications were observed. This 
supports the recommendation that routine 
anticoagulation treatment should be used in 
all patients who had AF post-operatively. 
The proportion of patients surviving 5 
and 15 years was 97.8 % and 89.5 %, re-
spectively, which was higher than in other 
series (Perek et al., 2011). A previous study 
reported that the leading causes of death are 
not related to CV disease in the long-term 
follow-up (D'Alfonso et al., 2008). But it’s 
not true in our study, for 4 (80 %) deaths 
were attributed to CV causes, i.e. cerebral 
hemorrhage and progressive HF. Based on 
the Logistic analysis, patients who com-
plained arthralgia or had no symptom and 
larger tumor volume correlated significant-
ly with mortality.  
Myxomas are usually considered be-
nign, but recurrence rate is around 5 % to 
20 % in sporadic and familial cases, which 
usually happens in 4 to 5 years post-
operative (Becker et al., 2008; Centofanti et 
al., 1999). In our series, only 3 (2.7 %) pa-
tients recurred at the original location or 
other chamber 3 to 18 years after the initial 
operation. The mechanisms behind recur-
rence may include incomplete surgical re-
moval, intraoperative dissemination, em-
bolization or regrowth in another location 
(Oliveira et al., 2010), but we found no vari-
able was correlated with it. To avoid the 
recurrence, most authors advise a full thick-
ness resection of the base of the tumor and 
examined heart chambers carefully to pre-
vent recurrence. This recommendation was 
not accepted by other authors who insisted 
that there was no difference in recurrence 
rates between patients who underwent an en 
bloc resection and a resection with only en-
docardial tissue attached with the tumor 
(Centofanti et al., 1999). In our study, the 
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lower recurrence rate of 2.7 % seemly sup-
ports the en bloc resection. 
Although recurrence is five times more 
common in familial subtypes, there was no 
familial case found in this study group. The 
mixing existing of typical myxoma and ma-
lignant cell in cardiac tumor and the malig-
nant change when it recurrs were reported 
by Cleveland and Kusumi separately 
(Cleveland et al., 1983; Kusumi et al., 
2009), but there was no malignant change 
in our series. 
 
CONCLUSION 
Cardiac myxoma was uncommon, but it 
is not rare in China. Just as in younger pa-
tient, the surgical resection of myxoma in 
the elderly is feasible with a low periopera-
tive mortality and low recurrence rate, so it 
should not be rejected merely duo to age-
ing. Cardiac myxomas are benign tumors, 
but they are considered clinically malignant 
tumors because of their susceptibility to 
embolize to distant organs. Unfortunately, 
few study on molecular mechanisms of tu-
morigenesis，recurrence  and embolism 
have done till now.  
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